Decision time: 28 October 2015, 9:00 a.m. Pacific. Knowledge cutoff: 27 October 2015, 11:59:59 p.m. Pacific. This packet uses only evidence public by that cutoff. It asks the Theranos board whether to continue patient testing and retail expansion, pause for independent validation, ring-fence a narrowly supported menu, or begin a partner-controlled strategic review.
Recommendation
Pause patient testing and retail expansion immediately. Preserve specimens, raw instrument logs, quality-control records, complaints, corrected and voided results, and clinician notifications. Commission an independent laboratory to validate every offered assay across its actual specimen, collection, transport, processing, device, site, operator, and reporting pathway against predeclared criteria. Permit a bounded relaunch only for combinations that pass. This is the high-confidence process recommendation in judgment.theranos.cutoff.pause-and-validate.
Do not estimate enterprise value, runway, loss capacity, or a target price. Current cash, revenue, burn, liabilities, capitalization, covenants, and contract economics are absent; the financial conclusion is abstention, not zero. See judgment.theranos.cutoff.financial-abstention and table.theranos.cutoff.financial-unknowns.
What the positive evidence supports
The commercial proposition was attractive. Theranos and Walgreens described CLIA-certified services using microsamples, extensive automation, hours-long turnaround, and prices at or below half of Medicare reimbursement rates. Those are interested-party claims, not independent validation. source · theranos.cutoff.walgreens-partnership-2013
There is also real, but narrow, regulatory evidence. FDA's decision summary supported substantial equivalence for the Theranos HSV-1 IgG assay with specified specimens, collection tubes, system, and intended use. Its fingerstick method-comparison table reported 97.4% sensitivity and 100% specificity for the stated samples. The conclusion applies to that defined assay—not the rest of a commercial menu. source · theranos.cutoff.fda-hsv1-2015
Theranos' public rebuttal claimed that its tests were accurate and reliable, that it had run more than 3.5 million tests, and that it had tens of thousands of satisfied customers. These remain company claims until reconciled to assay-level raw data, corrections, complaints, and representative independent testing. source · theranos.cutoff.techcrunch-response-2015
Why continuation fails the evidence gate
The broad claim and the available proof do not share the same perimeter. A peer-reviewed opinion paper characterized most company claims as exaggerated; a separate JAMA publication record made the peer-review transparency question visible. Neither is a controlled validation study, but both are disconfirming evidence that should have triggered a direct evidentiary response. source · theranos.cutoff.diamandis-2015 source · theranos.cutoff.ioannidis-2015
The public dispute was already affecting distribution. The frozen Longreads payload verifies the Wall Street Journal investigation's headline but does not contain the underlying article, so this packet does not reconstruct detailed allegations from it. Fortune separately reported that Walgreens was putting the brakes on expansion. source · theranos.cutoff.wsj-investigation-2015 source · theranos.cutoff.fortune-walgreens-2015
Most importantly, FDA had just released two Forms 483. They included observations that quality audits had not been performed, design validation did not ensure conformity to user needs and intended uses, and the design had not been validated under actual or simulated use conditions. FDA expressly said the forms contained inspectional observations rather than a final agency compliance determination. That legal status limits the conclusion, but it does not make the control signal immaterial. source · theranos.cutoff.fda-newark-483-2015 source · theranos.cutoff.fda-palo-alto-483-2015
The central conflict is therefore unresolved: broad company assurance versus narrow positive regulatory evidence, independent criticism, partner hesitation, and device-quality observations. It is explicitly preserved in conflict.theranos.cutoff.assurance-versus-validation and conflict.theranos.cutoff.clearance-scope; no inference from one assay closes either conflict.
Financial capacity
The only filed financing record in the cutoff packet is a 2010 Form D reporting a USD 100,000,005 offering and USD 45,000,000 sold. A Form D is an issuer notice, not an audited financial statement, and a five-year-old amount sold is not October 2015 cash. source · theranos.cutoff.form-d-2010
Accordingly, the board cannot determine whether remediation is financeable, how long liquidity lasts, what creditors or preferred holders control, or what partner obligations become due. The pause should therefore be paired with immediate bank verification, a 13-week cash forecast, capitalization and covenant reconstruction, and a partner-contract review. Until then, claim.theranos.cutoff.financial-capacity-unknown governs.
Alternatives and scenarios
Continuing and rebutting preserves near-term revenue and narrative momentum but exposes patients and partners while the decisive evidence is missing. Ring-fencing is viable only after the exact cleared or independently validated workflow is mapped to every offered result. A strategic review is prudent if independent remediation cannot be financed or partner trust cannot be restored.
The required contract forces scenario probabilities, but these are explicit judgmental weights rather than empirical base rates: 55% for a material validation shortfall, 30% for a narrow surviving menu, and 15% for a broad independent pass. They are governed by assumption.theranos.cutoff.validation-shortfall, assumption.theranos.cutoff.limited-valid-menu, and assumption.theranos.cutoff.broad-validation-pass. The recommendation does not depend on a precise point estimate: even the broad-pass branch benefits from evidence produced by the pause.
Release gates
No patient testing resumes until 100% of the offered assay-workflow combinations pass their independent criteria; any sentinel corrected or voided result triggers immediate review; no expansion occurs with an open decision-critical regulatory observation; and verified downside liquidity must cover at least twelve months of remediation. These are operating gates, not claims that public evidence currently satisfies them.
The board should reverse the pause only when the raw-data archive, quality system, patient-impact review, regulatory closure, partner terms, and financing package are independently verified. If those records cannot be produced, the board should move from remediation to the strategic-review alternative.
Limits
This packet does not assert that the Forms 483 were final violations, that contemporary news allegations were proven, that every assay was defective, or that the one cleared assay generalized to other tests. It also makes no valuation claim. Its conclusion is narrower: the evidence required to justify continued patient-facing scale was not present in the cutoff record, while the cost of learning through continued patient use was asymmetric.